Hemogenyx Pharmaceuticals Plc (HOPHF PINK) stock market data APIs
$2.3318
0(0%)
as of July 2, 2026
Try our APIs with
free plan!
Hemogenyx Pharmaceuticals Plc Financial Data Overview
Price chart is built with
Anychart
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. The company also treats for solid and rare cancers; and immune system and autoimmune diseases. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
Prev. Close
2.3318
Open
2.3318
High
2.3318
Low
2.3318
52 wk Range
1.24-2.33
Market Cap
15 844 K
Shares Outstanding
6 800 K
EPS
-0.0046
Beta
1.53
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Hemogenyx Pharmaceuticals Plc data using free add-ons & libraries
Get Hemogenyx Pharmaceuticals Plc Fundamental Data
Hemogenyx Pharmaceuticals Plc Fundamental data includes:
- Net Revenue:
- EBITDA: -6 784 214
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Hemogenyx Pharmaceuticals Plc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hemogenyx Pharmaceuticals Plc News
New
Hemogenyx signs LOI to explore CAR-T therapy commercialization in Estonia
Hemogenyx Pharmaceuticals (OTCPK:HOPHF [https://seekingalpha.com/symbol/HOPHF]) has signed [https://seekingalpha.com/pr/20240507-hemogenyx-pharmaceuticals-plc-signs-letter-of-intent] a letter of inten...
Hemogenyx Pharmaceuticals to issue convertible loan notes
* Hemogenyx Pharmaceuticals (OTCPK:HOPHF [https://seekingalpha.com/symbol/HOPHF]) issued convertible loan notes as the company continues the clinical trial of HG-CT-1, its CAR-T cell therapy for rel...
Get Hemogenyx Pharmaceuticals Plc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
